Cargando…
Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies
Cannabinoids are lipophilic substances derived from Cannabis sativa that can exert a variety of effects in the human body. They have been studied in cellular and animal models as well as in human clinical trials for their therapeutic benefits in several human diseases. Some of these include central...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664133/ https://www.ncbi.nlm.nih.gov/pubmed/37843213 http://dx.doi.org/10.4103/1673-5374.382220 |
_version_ | 1785138550309650432 |
---|---|
author | Duncan, R. Scott Riordan, Sean M. Gernon, Matthew C. Koulen, Peter |
author_facet | Duncan, R. Scott Riordan, Sean M. Gernon, Matthew C. Koulen, Peter |
author_sort | Duncan, R. Scott |
collection | PubMed |
description | Cannabinoids are lipophilic substances derived from Cannabis sativa that can exert a variety of effects in the human body. They have been studied in cellular and animal models as well as in human clinical trials for their therapeutic benefits in several human diseases. Some of these include central nervous system (CNS) diseases and dysfunctions such as forms of epilepsy, multiple sclerosis, Parkinson’s disease, pain and neuropsychiatric disorders. In addition, the endogenously produced cannabinoid lipids, endocannabinoids, are critical for normal CNS function, and if controlled or modified, may represent an additional therapeutic avenue for CNS diseases. This review discusses in vitro cellular, ex vivo tissue and in vivo animal model studies on cannabinoids and their utility as therapeutics in multiple CNS pathologies. In addition, the review provides an overview on the use of cannabinoids in human clinical trials for a variety of CNS diseases. Cannabinoids and endocannabinoids hold promise for use as disease modifiers and therapeutic agents for the prevention or treatment of neurodegenerative diseases and neurological disorders. |
format | Online Article Text |
id | pubmed-10664133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-106641332023-08-14 Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies Duncan, R. Scott Riordan, Sean M. Gernon, Matthew C. Koulen, Peter Neural Regen Res Review Cannabinoids are lipophilic substances derived from Cannabis sativa that can exert a variety of effects in the human body. They have been studied in cellular and animal models as well as in human clinical trials for their therapeutic benefits in several human diseases. Some of these include central nervous system (CNS) diseases and dysfunctions such as forms of epilepsy, multiple sclerosis, Parkinson’s disease, pain and neuropsychiatric disorders. In addition, the endogenously produced cannabinoid lipids, endocannabinoids, are critical for normal CNS function, and if controlled or modified, may represent an additional therapeutic avenue for CNS diseases. This review discusses in vitro cellular, ex vivo tissue and in vivo animal model studies on cannabinoids and their utility as therapeutics in multiple CNS pathologies. In addition, the review provides an overview on the use of cannabinoids in human clinical trials for a variety of CNS diseases. Cannabinoids and endocannabinoids hold promise for use as disease modifiers and therapeutic agents for the prevention or treatment of neurodegenerative diseases and neurological disorders. Wolters Kluwer - Medknow 2023-08-14 /pmc/articles/PMC10664133/ /pubmed/37843213 http://dx.doi.org/10.4103/1673-5374.382220 Text en Copyright: © Neural Regeneration Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Review Duncan, R. Scott Riordan, Sean M. Gernon, Matthew C. Koulen, Peter Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies |
title | Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies |
title_full | Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies |
title_fullStr | Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies |
title_full_unstemmed | Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies |
title_short | Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies |
title_sort | cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664133/ https://www.ncbi.nlm.nih.gov/pubmed/37843213 http://dx.doi.org/10.4103/1673-5374.382220 |
work_keys_str_mv | AT duncanrscott cannabinoidsandendocannabinoidsastherapeuticsfornervoussystemdisorderspreclinicalmodelsandclinicalstudies AT riordanseanm cannabinoidsandendocannabinoidsastherapeuticsfornervoussystemdisorderspreclinicalmodelsandclinicalstudies AT gernonmatthewc cannabinoidsandendocannabinoidsastherapeuticsfornervoussystemdisorderspreclinicalmodelsandclinicalstudies AT koulenpeter cannabinoidsandendocannabinoidsastherapeuticsfornervoussystemdisorderspreclinicalmodelsandclinicalstudies |